References
- 1. Azfar R, Gelfand J. Psoriasis and metabolic disease: Epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20(4):416-22.
- 2. Friedewald E, Cather C, Gelfand M, Gordon B, Gibbons H, Grundy S. AJCeditor's consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008;102(12):1631-43.
- 3. Goldhaber S. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56(1):1-7.
- 4. Machlus K, Aleman M, Wolberg A. Update on venous thromboembolism: risk factors, mechanisms, and treatments. Arterioscler Thrombb Vasc Biol. 2011;31(3):476-8.
- 5. Holst A, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010;121:1896-903.
- 6. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Eubom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19(3):225-30.
- 7. Reitsma P,Versteeg H, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol. 2012;32(3):563-8.
- 8. Kimball A, Gladman D, Gelfand J, Gordon K, Horn E, Korman N, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations forscreening. J Am Acad Dermatol . 2008;58(6):1031-42.
- 9. Komsa-Penkova R, Kovacheva-Kotseva K, Angelova S, Savov A, Simeonova M. [Selected methods of DNAanalysis and clinical applications]. 1st ed. Pleven: MU-Pleven; 2004. Bulgarian.
- 10. Lutsey P, Prizment A, Folsom A. Psoriasis is associated withagreater risk of incident venous thromboembolism: the Iowa Women's Health Study. JTromb Haemost. 2012;10(4):708-11.
- 11. Karabudak O, Eralp R, Akyol A, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol. 2008;88(4):337-40.
- 12. Ko JH, Lin JW, Hui RC. Acute pulmonary embolism inapatient with hypereosinophilia and psoriasis. Chang Gung Med J. 2011;34(6):17-23.
- 13.Vaughan D. PAI-1 and atherotrombosis. J Tromb Haemost. 2005;(8):1879-83.
- 14. Mehta R, Shapiro A. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008;14(6):1255-60.
- 15. Tsantes A, Nikolopoulos G, Bagos P, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5Gpolymorphism on the thrombotic risk. Thromb Res. 2008;122(6):736-42.
- 16. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. 2007;12(8):2957-66.
- 17. Juhan-Vague I, Alessi MC, Mavri A, Morange P. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1(7):1575-9.
- 18. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol. 2007;18(3):240-5.
- 19. Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P. Psoriasis and risk of venous thromboembolism:asystematic review and meta-analysis. QJM. 2014;107(10):793-7.
- 20. Catherine N, Chiu M. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119-32.
- 21. Harpel P, Zhang X, Borth W. Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J Nutr. 1996;126(4 Suppl):1285S-9S.
- 22. Casas J, Bautista L, Smeeth L, Sharma P, Hingorani A. Homocysteine and stroke: evidence onacausal link from mendelian randomisation. Lancеt. 2005;365(9455):224-32.
- 23.Wakkee M, Thio H, Prens E, Sijbrands E, Neumann H. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190(1):1-9.
- 24. Oh C, Das K, Gottlieb A. Treatment with antitumor necrosis factorα (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. JAm Acad Dermatol. 2000;42(5):829-30.
- 25. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2012;147:179-87.